Alimera Sciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $14.93 million
- Book Value:
- Revenue TTM:
- $54.06 million
- Operating Margin TTM:
- Gross Profit TTM:
- $52.00 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Alimera Sciences Inc had its IPO on 2010-04-22 under the ticker symbol ALIM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Alimera Sciences Inc has a staff strength of 145 employees.
Shares of Alimera Sciences Inc opened at $1.9 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $1.78 - $1.93, and closed at $1.78.
This is a -5.82% slip from the previous day's closing price.
A total volume of 19,313 shares were traded at the close of the day’s session.
In the last one week, shares of Alimera Sciences Inc have increased by +31.85%.
Alimera Sciences Inc's Key Ratios
Alimera Sciences Inc has a market cap of $14.93 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.2917.
In the last 12-months Alimera Sciences Inc’s revenue was $54.06 million with a gross profit of $52.00 million and an EBITDA of $-9602000. The EBITDA ratio measures Alimera Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alimera Sciences Inc’s operating margin was -22.72% while its return on assets stood at -14.84% with a return of equity of 0%.
In Q3, Alimera Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 11.9%.
Alimera Sciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.05 per share while it has a forward price to earnings multiple of 60.6061 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alimera Sciences Inc’s profitability.
Alimera Sciences Inc stock is trading at a EV to sales ratio of 1.4791 and a EV to EBITDA ratio of -7.8817. Its price to sales ratio in the trailing 12-months stood at 0.2917.
Alimera Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $43.43 million
- Total Liabilities
- $34.01 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Alimera Sciences Inc ended 2023 with $43.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $43.43 million while shareholder equity stood at $-18078000.00.
Alimera Sciences Inc ended 2023 with $0 in deferred long-term liabilities, $34.01 million in other current liabilities, 70000.00 in common stock, $-411608000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.51 million and cash and short-term investments were $5.51 million. The company’s total short-term debt was $21,643,000 while long-term debt stood at $22.49 million.
Alimera Sciences Inc’s total current assets stands at $29.76 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $19.14 million compared to accounts payable of $8.71 million and inventory worth $1.79 million.
In 2023, Alimera Sciences Inc's operating cash flow was $-130000.00 while its capital expenditure stood at $130000.
Comparatively, Alimera Sciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Alimera Sciences Inc stock is currently trading at $1.78 per share. It touched a 52-week high of $7.92 and a 52-week low of $7.92. Analysts tracking the stock have a 12-month average target price of $6.75.
Its 50-day moving average was $2.21 and 200-day moving average was $4.32 The short ratio stood at 1.99 indicating a short percent outstanding of 0%.
Around 1999.7% of the company’s stock are held by insiders while 3246.4% are held by institutions.
Frequently Asked Questions About Alimera Sciences Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.